237 related articles for article (PubMed ID: 28544622)
1. An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.
Dimier N; Todd S
Pharm Stat; 2017 Sep; 16(5):322-333. PubMed ID: 28544622
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the information theory approach to evaluating time-to-event surrogate and true endpoints in a meta-analytic setting.
Dimier N; Todd S
Pharm Stat; 2021 Mar; 20(2):335-347. PubMed ID: 33145928
[TBL] [Abstract][Full Text] [Related]
3. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
Rotolo F; Paoletti X; Michiels S
Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
[TBL] [Abstract][Full Text] [Related]
4. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
Baker SG
Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
[TBL] [Abstract][Full Text] [Related]
5. Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data.
Le Coënt Q; Legrand C; Rondeau V
Biostatistics; 2023 Dec; 25(1):98-116. PubMed ID: 36398615
[TBL] [Abstract][Full Text] [Related]
6. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
7. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T
Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941
[TBL] [Abstract][Full Text] [Related]
8. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
Sofeu CL; Emura T; Rondeau V
Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
[TBL] [Abstract][Full Text] [Related]
9. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
10. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
Tanaka S; Matsuyama Y; Ohashi Y
Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
[TBL] [Abstract][Full Text] [Related]
11. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
12. An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error.
Belhechmi S; Michiels S; Paoletti X; Rotolo F
Contemp Clin Trials Commun; 2019 Sep; 15():100402. PubMed ID: 31338479
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.
Medeiros FA
Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO20-BIO26. PubMed ID: 28475699
[TBL] [Abstract][Full Text] [Related]
14. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
Sofeu CL; Rondeau V
PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
[TBL] [Abstract][Full Text] [Related]
15. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation.
Burzykowski T; Buyse M
Pharm Stat; 2006; 5(3):173-86. PubMed ID: 17080751
[TBL] [Abstract][Full Text] [Related]
16. Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation.
Papanikos T; Thompson JR; Abrams KR; Bujkiewicz S
Stat Med; 2022 Nov; 41(25):4961-4981. PubMed ID: 35932152
[TBL] [Abstract][Full Text] [Related]
17. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.
Bujkiewicz S; Thompson JR; Spata E; Abrams KR
Stat Methods Med Res; 2017 Oct; 26(5):2287-2318. PubMed ID: 26271918
[TBL] [Abstract][Full Text] [Related]
18. A rank test for bivariate time-to-event outcomes when one event is a surrogate.
Shaw PA; Fay MP
Stat Med; 2016 Aug; 35(19):3413-23. PubMed ID: 27059817
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
Shi Q; Sargent DJ
Int J Clin Oncol; 2009 Apr; 14(2):102-11. PubMed ID: 19390940
[TBL] [Abstract][Full Text] [Related]
20. An information-theoretic approach to surrogate-marker evaluation with failure time endpoints.
Pryseley A; Tilahun A; Alonso A; Molenberghs G
Lifetime Data Anal; 2011 Apr; 17(2):195-214. PubMed ID: 20878357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
